NEW YORK, March 18, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies (OTC:AXIM), an industrial hemp biosciences industry leader, welcomes Dr. Jacques F. Meis, MD, PhD, world-renowned infectious disease specialist, to the Company's medical advisory board.
Photos accompanying this release are available at
http://www.globenewswire.com/newsroom/prs/?pkgid=31508
http://www.globenewswire.com/newsroom/prs/?pkgid=31509
http://www.globenewswire.com/newsroom/prs/?pkgid=31510
Dr. Meis is the co-author of approximately 350 peer reviewed US National Library of Medicine (PubMed)-listed publications. His current research focuses on the diagnosis, treatment, molecular typing and antifungal susceptibility of the opportunistic fungi Aspergillus, Cryptococcus and Candida in addition to other rare filamentous fungi. Dr. Meis' appointment is an important addition to the AXIM advisory board, advancing the Company's global mission to research and develop cannabinoid-based products that address conditions for which there currently are no effective treatments.
"We are extremely pleased to inform the public and shareholders that Dr. Jacques F. Meis has joined AXIM's medical advisory board," states George E. Anastassov, MD, DDS, MBA and Chief Executive Officer for AXIM Biotechnologies. "Dr. Meis will be working with us on novel antibiotics utilizing CBG and other cannabinoids in the fight against MRSA and other infectious diseases."
Jacques F. Meis MD, PhD is a Netherlands-based consultant microbiologist at Canisius-Wilhelmina Hospital in Nijmegen, a prominent teaching hospital. Dr. Meis is also an honorary consultant at the Radboud University Nijmegen Medical Centre, a board certified medical specialist in the Netherlands, and a Fellow of the Infectious Diseases Society of America and the Royal College of Pathology (UK). Dr. Meis' vast medical experience also includes roles as:
- Past President of the Dutch Society for Medical Mycology
- Past President of the European Confederation for Medical Mycology
- Past Chairman of the External Quality Control Program in Bacteriology and Mycology (the Netherlands)
- Senior Editor of Mycoses and present voting member on the CLSI Subcommittee on Antifungal Susceptibility Testing
At a recent press conference, AXIM unveiled the world's first hemp cannabigerol (CBG)-based oral care and cosmetic products – including the RENECANN™ brand – as featured by Fox Business Network, Crain's New York, MainStreet.com, and MJFreeway.com. The following is a list of some of the groundbreaking, retail-ready hemp CBG-infused products from AXIM Biotech:
- Toothpaste
- Mouthwash
- Dentifrice
- Oral Gel (for minor cuts and sores)
- Diaper Rash Cream
- Moisturizers
- Lotions
- Lip Balm
- Shampoo
- Conditioner
- Body Wash
- Day Cream
- Night Cream
- Eye Cream
To arrange for media interviews, please contact Andrew Hard, Public Relations Spokesperson, via email at Andrew.Hard@AXIMBiotech.com or call 858-380-5478.
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US CSA). The company does grow, sell, and distribute hemp-based products.
The photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.
